These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 37183837

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.
    Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
    [Abstract] [Full Text] [Related]

  • 6. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L.
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [Abstract] [Full Text] [Related]

  • 7. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
    Sun XS, Wang Z, Ren SH, Zhang HL, Liu LJ, Du HB, Liu XW, Liu JF.
    Thorac Cancer; 2022 Sep; 13(17):2429-2435. PubMed ID: 35859328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L.
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [Abstract] [Full Text] [Related]

  • 10. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC.
    Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
    Zou D, Guo M, Zhou Q.
    BMC Cancer; 2021 Jun 02; 21(1):661. PubMed ID: 34078317
    [Abstract] [Full Text] [Related]

  • 14. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
    Zhang JY, Liu YX, Wang H, Mi L, Song GH, Jiang HF, Yan Y, Shao B, Kong WY, Zhang RY, Ran R, Liu XR, Wang J, Lin YT, Li HP.
    Zhonghua Yi Xue Za Zhi; 2018 Sep 11; 98(34):2718-2721. PubMed ID: 30220167
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y, Liang Y, Li H.
    BMC Cancer; 2023 Jul 26; 23(1):702. PubMed ID: 37495949
    [Abstract] [Full Text] [Related]

  • 16. Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study.
    You J, Yuan Y, Gu X, Wang W, Li X.
    BMC Cancer; 2024 Jul 12; 24(1):833. PubMed ID: 38997665
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 12; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
    Jiang ZF, Xu FR, Fan J, Li BJ, Gao JN, Hu JW, Wang XJ, Zhang YQ, Wang JH, Li F, Liu Q, Liu YH, Wang S, Wang YS, Ouyang QC, Hu B, Sun GP, Zhang Y, Zang AM, Fan PZ, Wu CP, Liu J, Zhang HW, Wang W, Hu XC, Tang LL, Zhang J, Bao YY, Geng CZ, Sun Q, Zhang F, Yin YM, Jiang HC, An YH.
    Zhonghua Yi Xue Za Zhi; 2018 Apr 24; 98(16):1231-1235. PubMed ID: 29747310
    [Abstract] [Full Text] [Related]

  • 20. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.
    Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P.
    Br J Clin Pharmacol; 2024 Oct 24; 90(10):2621-2629. PubMed ID: 38925586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.